4-Methylmorpholine → HCID 135547994, compound
Reaction equation
[CH3:1][O:2][C:3]1[CH:8]=[C:7]([O:9][CH3:10])[CH:6]=[CH:5][C:4]=1[CH:11]1[S:17][C:16]([CH3:19])([CH3:18])[CH:15]([C:20](O)=[O:21])[N:14]=[C:13]([C:23]2[C:24](=[O:31])[O:25][C:26]([CH3:30])=[CH:27][C:28]=2[OH:29])[CH2:12]1.CN1CCOCC1.C1CN([P+](ON2N=NC3C=CC=CC2=3)(N2CCCC2)N2CCCC2)CC1.F[P-](F)(F)(F)(F)F.[C:72]([O:76][C:77](=[O:81])[CH:78]([NH2:80])[CH3:79])([CH3:75])([CH3:74])[CH3:73]>CN(C=O)C>[C:72]([O:76][C:77](=[O:81])[CH:78]([NH:80][C:20]([CH:15]1[N:14]=[C:13]([C:23]2[C:24](=[O:31])[O:25][C:26]([CH3:30])=[CH:27][C:28]=2[OH:29])[CH2:12][CH:11]([C:4]2[CH:5]=[CH:6][C:7]([O:9][CH3:10])=[CH:8][C:3]=2[O:2][CH3:1])[S:17][C:16]1([CH3:18])[CH3:19])=[O:21])[CH3:79])([CH3:75])([CH3:74])[CH3:73]Participants
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
7-(2,4-Dimethoxy-phenyl)-5-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-2,2-dimethyl-2,3,6,7-tetrahydro-[1,4]thiazepine-3-carboxylic acid (0.03 g), prepared as in Example 2, was dissolved in DMF (2 mL) and 2-amino-propionic acid tert-butyl ester (0.012 g), N-methylmorpholine (0.2 ml) and PyBOP (0.034 g) were added to the solution at room temperature. The mixture was stirred while the progress of the reaction was followed by analytical HPLC and when complete (16 hours) the solvent was removed in vacuo. Purification of product by preparative HPLC (RPC18 column, 2-70% acetonitrile/water containing 0.1% HCl) provided 2-({1-[7-(2,4-dimethoxy-phenyl)-5-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-2,2-dimethyl-2,3,6,7-tetrahydro-[1,4]thiazepin-3-yl]-methanoyl }-amino)-propionic acid tert-butyl ester (18 mg) as an off-white powder. LCMS: M+ 575.0.
Workup
- customwas followed by analytical HPLC and when complete (16 hours)
- customwas removed in vacuo
- customPurification of product by preparative HPLC (RPC18 column, 2-70% acetonitrile/water containing 0.1% HCl)
Sources & evidence
- ORD record
- ord-5b00cdddca5e48769cc8148073132feb
- Source dataset
- uspto-grants-2005_03
- Patent number
- US06861419B2
Reaction notes
Loading…